A randomized controlled clinical trial evaluating the effect of Trigonella foenum-graecum (fenugreek) versus glibenclamide in patients with diabetes

Background: Herbal medicines long have been used in the management of diabetes mellitus (DM). Objective: This study was conducted to ascertain if fenugreek compared with glibenclamide had any impacts on controlling blood glucose in patients with uncontrolled type II DM on conventional therapy. Metho...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:African health sciences Ročník 19; číslo 1; s. 1594 - 1601
Hlavní autoři: Najdi, Rania A, Hagras, Magda M, Kamel, Fatemah O, Magadm, Rania M
Médium: Journal Article
Jazyk:angličtina
Vydáno: Uganda Makerere University Medical School 01.03.2019
Makerere Medical School
Témata:
ISSN:1680-6905, 1729-0503, 1680-6905, 1729-0503
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Background: Herbal medicines long have been used in the management of diabetes mellitus (DM). Objective: This study was conducted to ascertain if fenugreek compared with glibenclamide had any impacts on controlling blood glucose in patients with uncontrolled type II DM on conventional therapy. Methods: A total of 12 patients with uncontrolled DM and on metformin were recruited and divided into two groups. Patients in group 1 received 2 g fenugreek per day, whereas those in group 2 received glibenclamide 5 mg once daily. The impacts of fenugreek on the glycemic control and lipid profile were measured before initiation of the regimen and then after 12 weeks. Results: Only 9 of the 12 study participants completed the study. Fenugreek at 2 g/day caused an insignificant drop in fasting blood glucose (P = 0.63), but the fasting insulin level increased significantly (P = 0.04). The ratio of high- to low-density lipoprotein was significantly decreased from before to after treatment (P = 0.006). Fenugreek did not cause any notable adverse impacts on hepatic and renal functions throughout the study. Conclusion: Fenugreek could be used as adjuvant therapy to anti-diabetic drugs to control blood glucose, and further studies are needed. DOI: https://dx.doi.org/10.4314/ahs.v19i1.34 Cite as: Najdi RA, Hagras MM, Kamel FO, RM M. A randomized controlled clinical trial evaluating the effect of Trigonella foenum-graecum (fenugreek) versus glibenclamide in patients with diabetes. Afri Health Sci. 2019;19(1). 1594-1601. https://dx.doi.org/10.4314/ahs.v19i1.34
AbstractList Herbal medicines long have been used in the management of diabetes mellitus (DM). This study was conducted to ascertain if fenugreek compared with glibenclamide had any impacts on controlling blood glucose in patients with uncontrolled type II DM on conventional therapy. A total of 12 patients with uncontrolled DM and on metformin were recruited and divided into two groups. Patients in group 1 received 2 g fenugreek per day, whereas those in group 2 received glibenclamide 5 mg once daily. The impacts of fenugreek on the glycemic control and lipid profile were measured before initiation of the regimen and then after 12 weeks. Only 9 of the 12 study participants completed the study. Fenugreek at 2 g/day caused an insignificant drop in fasting blood glucose (P = 0.63), but the fasting insulin level increased significantly (P = 0.04). The ratio of high- to low-density lipoprotein was significantly decreased from before to after treatment (P = 0.006). Fenugreek did not cause any notable adverse impacts on hepatic and renal functions throughout the study. Fenugreek could be used as adjuvant therapy to anti-diabetic drugs to control blood glucose, and further studies are needed.
Herbal medicines long have been used in the management of diabetes mellitus (DM).BACKGROUNDHerbal medicines long have been used in the management of diabetes mellitus (DM).This study was conducted to ascertain if fenugreek compared with glibenclamide had any impacts on controlling blood glucose in patients with uncontrolled type II DM on conventional therapy.OBJECTIVEThis study was conducted to ascertain if fenugreek compared with glibenclamide had any impacts on controlling blood glucose in patients with uncontrolled type II DM on conventional therapy.A total of 12 patients with uncontrolled DM and on metformin were recruited and divided into two groups. Patients in group 1 received 2 g fenugreek per day, whereas those in group 2 received glibenclamide 5 mg once daily. The impacts of fenugreek on the glycemic control and lipid profile were measured before initiation of the regimen and then after 12 weeks.METHODSA total of 12 patients with uncontrolled DM and on metformin were recruited and divided into two groups. Patients in group 1 received 2 g fenugreek per day, whereas those in group 2 received glibenclamide 5 mg once daily. The impacts of fenugreek on the glycemic control and lipid profile were measured before initiation of the regimen and then after 12 weeks.Only 9 of the 12 study participants completed the study. Fenugreek at 2 g/day caused an insignificant drop in fasting blood glucose (P = 0.63), but the fasting insulin level increased significantly (P = 0.04). The ratio of high- to low-density lipoprotein was significantly decreased from before to after treatment (P = 0.006). Fenugreek did not cause any notable adverse impacts on hepatic and renal functions throughout the study.RESULTSOnly 9 of the 12 study participants completed the study. Fenugreek at 2 g/day caused an insignificant drop in fasting blood glucose (P = 0.63), but the fasting insulin level increased significantly (P = 0.04). The ratio of high- to low-density lipoprotein was significantly decreased from before to after treatment (P = 0.006). Fenugreek did not cause any notable adverse impacts on hepatic and renal functions throughout the study.Fenugreek could be used as adjuvant therapy to anti-diabetic drugs to control blood glucose, and further studies are needed.CONCLUSIONFenugreek could be used as adjuvant therapy to anti-diabetic drugs to control blood glucose, and further studies are needed.
Background: Herbal medicines long have been used in the management of diabetes mellitus (DM). Objective: This study was conducted to ascertain if fenugreek compared with glibenclamide had any impacts on controlling blood glucose in patients with uncontrolled type II DM on conventional therapy. Methods: A total of 12 patients with uncontrolled DM and on metformin were recruited and divided into two groups. Patients in group 1 received 2 g fenugreek per day, whereas those in group 2 received glibenclamide 5 mg once daily. The impacts of fenugreek on the glycemic control and lipid profile were measured before initiation of the regimen and then after 12 weeks. Results: Only 9 of the 12 study participants completed the study. Fenugreek at 2 g/day caused an insignificant drop in fasting blood glucose (P = 0.63), but the fasting insulin level increased significantly (P = 0.04). The ratio of high- to low-density lipoprotein was significantly decreased from before to after treatment (P = 0.006). Fenugreek did not cause any notable adverse impacts on hepatic and renal functions throughout the study. Conclusion: Fenugreek could be used as adjuvant therapy to anti-diabetic drugs to control blood glucose, and further studies are needed. DOI: https://dx.doi.org/10.4314/ahs.v19i1.34 Cite as: Najdi RA, Hagras MM, Kamel FO, RM M. A randomized controlled clinical trial evaluating the effect of Trigonella foenum-graecum (fenugreek) versus glibenclamide in patients with diabetes. Afri Health Sci. 2019;19(1). 1594-1601. https://dx.doi.org/10.4314/ahs.v19i1.34
Author Najdi, Rania A
Hagras, Magda M
Kamel, Fatemah O
Magadm, Rania M
AuthorAffiliation 1 Pharmacology Department, Faculty of Medicine, KAU, Jeddah, Saudi Arabia
2 Pharmacology department, Faculty of Medicine, Suez Canal University, Egypt
AuthorAffiliation_xml – name: 2 Pharmacology department, Faculty of Medicine, Suez Canal University, Egypt
– name: 1 Pharmacology Department, Faculty of Medicine, KAU, Jeddah, Saudi Arabia
Author_xml – sequence: 1
  fullname: Najdi, Rania A
– sequence: 2
  fullname: Hagras, Magda M
– sequence: 3
  fullname: Kamel, Fatemah O
– sequence: 4
  fullname: Magadm, Rania M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31148988$$D View this record in MEDLINE/PubMed
BookMark eNp1kU2PFCEQholZ437ozbPhuCb22Hx0D1xMNhu_kk28rGdC00UPSsMI9Bj9Hf5gGWdns5qYECjgqbcq9Z6jkxADIPSctCvOCH-tN3m1I9KRFeOP0BnpRdv0su1OHsSn6DznL21LeyLJE3TKCOFCCnGGfl3hpMMYZ_cTRmxiKCl6vw-9C85oj0tydYed9osuLky4bACDtWAKjhbfJjfVhrzX2EYIy9xMSYNZZnxp63VKAF9f4h2kvGQ8eTdAMF7PbgTsAt5WSQgl4--ubPDo9AAF8lP02Gqf4dndeYE-v3t7e_2hufn0_uP11U0zcMpKY6zVgndyXVc_8N7I1kg7cmqYoJRRGC2VXSeEINSuje5pv6ZAdCXsWlbqAr056G6XYYbR1E6S9mqb3KzTDxW1U3__BLdRU9ypvmNEsr4KXN4JpPhtgVzU7LLZDyNAXLKqXTDBJWm7ir54WOu-yNGKCtADYFLMOYFVxpU6nr0l2nlFWrX3W1W_1R-_FeM16dU_SUfd_-CrAz64WP2Fe9pUk9XxsWZsMpEtY-w3GmrC0g
CitedBy_id crossref_primary_10_1016_j_phrs_2022_106594
crossref_primary_10_1080_10408398_2019_1635567
crossref_primary_10_3390_ph16040515
crossref_primary_10_3390_ijms25063385
crossref_primary_10_1007_s40200_020_00628_8
crossref_primary_10_1007_s40200_022_01171_4
crossref_primary_10_29219_fnr_v68_10667
crossref_primary_10_31083_j_fbs1501004
crossref_primary_10_1002_fsn3_4440
crossref_primary_10_3389_fphar_2022_821810
crossref_primary_10_2174_0122150838358231241129094038
crossref_primary_10_1111_1750_3841_16970
crossref_primary_10_1016_j_jep_2021_113984
crossref_primary_10_1016_j_fbio_2022_101546
crossref_primary_10_1016_j_phymed_2021_153614
crossref_primary_10_3390_app14209195
crossref_primary_10_7717_peerj_14639
crossref_primary_10_3390_ph18020279
crossref_primary_10_1002_ptr_7817
crossref_primary_10_1016_j_heliyon_2024_e39699
crossref_primary_10_3390_pharmaceutics14112453
crossref_primary_10_1007_s10787_022_01087_8
crossref_primary_10_63096_medtigo3061235
crossref_primary_10_1002_ptr_6690
crossref_primary_10_3390_ijerph19074188
crossref_primary_10_1186_s13020_021_00467_6
crossref_primary_10_1002_ptr_7564
crossref_primary_10_1093_bbb_zbab012
crossref_primary_10_1055_s_0044_1801764
crossref_primary_10_3390_nu15234867
crossref_primary_10_1016_j_jafr_2025_101835
crossref_primary_10_1186_s13098_022_00848_3
crossref_primary_10_1186_s13098_021_00633_8
ContentType Journal Article
Copyright Copyright 2019 - Najdi et al.
2019 Najdi et al. 2019
Copyright_xml – notice: Copyright 2019 - Najdi et al.
– notice: 2019 Najdi et al. 2019
DBID RBI
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.4314/ahs.v19i1.34
DatabaseName Bioline International
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1680-6905
1729-0503
EndPage 1601
ExternalDocumentID PMC6531936
31148988
10_4314_ahs_v19i1_34
cria_bioline_hs_hs19033
Genre Randomized Controlled Trial
Journal Article
GroupedDBID ---
-OY
23M
2WC
4JU
53G
5GY
6J9
AAFWJ
ABVJJ
ACGFO
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CS3
DIK
E3Z
EBD
EBS
EJD
EMOBN
F5P
GX1
HYE
KWQ
M48
MK0
M~E
OK1
OVT
P2P
RBI
RNS
RPM
SV3
TR2
AAYXX
ANHLU
CITATION
C1A
CGR
CUY
CVF
ECM
EIF
NPM
OPA
OVD
TEORI
WOQ
7X8
5PM
ID FETCH-LOGICAL-b423t-cffa845975976b46c90c9fd42c382232edf295588812f7ca62672e1ad42f792c3
ISICitedReferencesCount 39
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000465469000034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1680-6905
1729-0503
IngestDate Tue Nov 04 01:58:39 EST 2025
Thu Oct 02 06:20:13 EDT 2025
Wed Feb 19 02:27:02 EST 2025
Sat Nov 29 01:35:47 EST 2025
Tue Nov 18 22:00:45 EST 2025
Tue Jul 01 18:08:23 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords diabetes
glibenclamide
Trigonella foenum-graecum (fenugreek)
Language English
License Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b423t-cffa845975976b46c90c9fd42c382232edf295588812f7ca62672e1ad42f792c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Email addresses: Rania A Najdi (rania.magadmi@yahoo.com); Magda M Hagras, MBBS PhD (Magyhagras@hotmail.com); Fatemah O Kamel, MBBS MSc PhD (fokamel@kau.edu.sa); Rania M Magadmi, MBBS PhD (rmagadmi@kau.edu.sa).
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC6531936
PMID 31148988
PQID 2233849105
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6531936
proquest_miscellaneous_2233849105
pubmed_primary_31148988
crossref_citationtrail_10_4314_ahs_v19i1_34
crossref_primary_10_4314_ahs_v19i1_34
bioline_primary_cria_bioline_hs_hs19033
PublicationCentury 2000
PublicationDate 2019-03-01
PublicationDateYYYYMMDD 2019-03-01
PublicationDate_xml – month: 03
  year: 2019
  text: 2019-03-01
  day: 01
PublicationDecade 2010
PublicationPlace Uganda
PublicationPlace_xml – name: Uganda
– name: Kampala, Uganda
PublicationTitle African health sciences
PublicationTitleAlternate Afr Health Sci
PublicationYear 2019
Publisher Makerere University Medical School
Makerere Medical School
Publisher_xml – name: Makerere University Medical School
– name: Makerere Medical School
SSID ssj0026191
Score 2.380419
Snippet Background: Herbal medicines long have been used in the management of diabetes mellitus (DM). Objective: This study was conducted to ascertain if fenugreek...
Herbal medicines long have been used in the management of diabetes mellitus (DM). This study was conducted to ascertain if fenugreek compared with...
Herbal medicines long have been used in the management of diabetes mellitus (DM).BACKGROUNDHerbal medicines long have been used in the management of diabetes...
SourceID pubmedcentral
proquest
pubmed
crossref
bioline
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1594
SubjectTerms Adult
Aged
Blood Glucose - drug effects
Blood Glucose - metabolism
diabetes
Diabetes Mellitus, Type 2 - diagnosis
Diabetes Mellitus, Type 2 - drug therapy
Dose-Response Relationship, Drug
Female
glibenclamide
Glyburide - chemistry
Glycated Hemoglobin A - drug effects
Humans
Hypoglycemic Agents - pharmacology
Hypoglycemic Agents - therapeutic use
Lipids - blood
Male
Middle Aged
Phytotherapy - methods
Plant Extracts - chemistry
Plant Extracts - pharmacology
Plant Extracts - therapeutic use
Seeds
Treatment Outcome
Trigonella - chemistry
Trigonella foenum-graecum (fenugreek)
Title A randomized controlled clinical trial evaluating the effect of Trigonella foenum-graecum (fenugreek) versus glibenclamide in patients with diabetes
URI http://www.bioline.org.br/abstract?id=hs19033
https://www.ncbi.nlm.nih.gov/pubmed/31148988
https://www.proquest.com/docview/2233849105
https://pubmed.ncbi.nlm.nih.gov/PMC6531936
Volume 19
WOSCitedRecordID wos000465469000034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1680-6905
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0026191
  issn: 1680-6905
  databaseCode: M~E
  dateStart: 20030101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6lBVW9IN6ER7VIIECWS2I79voYVa2QIKFCAfVmbfaRhCZOlJcqDvwK_iw3ZrxeP1IOgIRkWdFms2tnPs_ON56ZJeRFmzPJvZZwtSeVGyjhu7AKBq6vW0xHSmqWOfS_fIj6fXZxEZ83Gj9tLsx2GqUpu7qKF_9V1NAGwsbU2b8QdzEoNMBnEDqcQexw_iPBdx1YfuR8NvmmpI1En-JHmwNpNuqwZb7zbCkT14Gm4wD4-hyDX7ij5xgo746WXInNDI1RDQ3A0NUlehMwomOzckYYopIKgNZEZiVI8lqteeKc9e5WzWCzO1GaZ2E6-TJcmPd9_lVmUQafOCaNdUs1CZdi3ON8JHnpyX3PZyba4IxjXeqx87H0tI-4nFUG61X9HJha5Vf9HD1-qZYKdzrIX2CZKqUV1R0yIMJxy7wjV6YNqIOLFW9q-j6-hmujvMGyCyqGQDs00-8uMmByBbiCjlfH23Y8aR8bb2wFWotZhi0fuWZsdi3cKep93jsJUfv54R654UWdGBVy7_tp4SsAXpv5CuxNmZwNnPptdeJDcmBnAQKHdbuAm9RNrGu8aTf8t2JPDW6TWzkRol0D4DukodK75KCXh3rcIz-6tMQxLXFMLY5phmNa4pgCjqnBMZ1rWuKY1nFMXxcofkMNhmkNw3SSUothihimFsP3yeez08HJOzffQsQdAk9Yu0JrzgIgzXCEwyAUcUvEWgae8MEy9j1QRl7c6TAGdq6OBAd6H3mqzaGHjmLo9YDsp3CtjwgFDaYCJoaelDJoKzGMQ9B_UaT00Fce403yKv__k4UpFJPAus8T2zhewQHmt-83iWPlk4i8Ej9uCDNNgJGjiBMQcZKJOPGDJnlZ9LYD_77fcyvqBJYIfO_HUzXfrBK4UZ8FwAs6TfLQiL4YyaKnSaIaKIoOWH6-_k06GWdl6HMAP_7nXz4hh-WD_pTsr5cb9YzcFNv1ZLU8InvRBTvKnopfR6oM8A
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+randomized+controlled+clinical+trial+evaluating+the+effect+of+Trigonella+foenum-graecum+%28fenugreek%29+versus+glibenclamide+in+patients+with+diabetes&rft.jtitle=African+health+sciences&rft.au=Najdi%2C+Rania+A&rft.au=Hagras%2C+Magda+M&rft.au=Kamel%2C+Fatemah+O&rft.au=Magadmi%2C+Rania+M&rft.date=2019-03-01&rft.pub=Makerere+Medical+School&rft.issn=1680-6905&rft.eissn=1729-0503&rft.volume=19&rft.issue=1&rft.spage=1594&rft.epage=1601&rft_id=info:doi/10.4314%2Fahs.v19i1.34&rft_id=info%3Apmid%2F31148988&rft.externalDocID=PMC6531936
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1680-6905&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1680-6905&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1680-6905&client=summon